Two of AstraZeneca’s Best-Selling Medicines Show Advances in Deadly Ailments
Imfinzi, a cancer drug, won approval from the U.S. Food and Drug Administration to treat extensive-stage small cell lung cancer, one of the most deadly forms of lung cancer.
Imfinzi is one of a number of new products that have made AstraZeneca into a redoubt of cancer treatments
Two of AstraZeneca Plc’s best-selling medicines showed advances in lethal diseases.
Imfinzi, a cancer drug, won approval from the U.S. Food and Drug Administration to treat extensive-stage small cell lung cancer, one of the most deadly forms of lung cancer.
Imfinzi is one of a number of new products that have made AstraZeneca into a redoubt of cancer treatments -- challenging established rivals like Roche Holding AG -- and sent the shares rising almost 40% in the past two years.
The U.K. drugmaker also said its diabetes drug Farxiga showed “overwhelming efficacy" earlier than expected in a clinical trial on patients with chronic kidney disease, leading Astra to stop it early.
(Except for the headline, this story has not been edited by Scrabbl staff and is published from a syndicated feed.)